Jingtai Technology Financing AI Medicine is optimistic about artificial intelligence-driven drug development

On January 24th, AI Pharmaceutical R&D company XtalPi announced that it has completed approximately $15 million in Series B financing in the near future. This round of financing was led by Sequoia Capital China Fund (hereinafter referred to as “Sequoia China”). , Google and investment, A round of investment, Tencent continues to invest in this round. At this point, Jingtai Technology's total financing exceeded 20 million US dollars.

Founded in 2014 on the MIT campus, Jingtai Technology is committed to computing innovation and is committed to creating a new generation of Intelligent Drug Discovery and Development (ID4) technology to address efficiency and success rates in preclinical research. problem. The company combines quantum physics, artificial intelligence and ultra-large-scale cloud computing to achieve fast and accurate prediction of important characteristics of small molecule drugs, and has many industry-leading technologies in drug design and drug solid-phase screening. The existing investors of Jingtai Technology also include Zhenge Fund and Fengrui Capital. The company has established stable and in-depth cooperation with a number of pharmaceutical companies and new drug research institutions, and has made a number of progress.

Wentai Hao, co-founder and chairman of Jingtai Technology, said: “Jingtai Technology has always believed that the power of algorithms can bring more rapid and efficient drug research and development technology, and promote the informationization and intelligent upgrade of the pharmaceutical industry. I hope our technology can become Accelerating engines for drug R&D innovation at home and abroad, breaking through the long-standing challenges and limitations of traditional R&D models, enabling more high-quality and efficient drugs to reach patients faster. Can obtain artificial intelligence and computer science from Sequoia China, Google, Tencent. The support of top investors in the field is a great affirmation of our technology, and we are very much looking forward to further cooperation with them in the future."

After completing this round of financing, Jingtai Technology will give full play to its existing technological advantages, continue to promote cooperative research and development projects with international pharmaceutical companies and research institutions, and expand to the upstream and downstream links of drug research and development. On the one hand, Jingtai Technology will build a crystallization laboratory guided by high-precision prediction, giving drug developers unprecedented drug solid-phase design capabilities, thereby further improving R&D efficiency and project success rate; Accuracy calculation data develops new algorithm applications and provides a richer solution for new drug development.

Shen Nanpeng, global managing partner of Sequoia Capital, said: “The technological innovation of Jingtai Technology provides a unique solution for the pain points and bottlenecks caused by the high degree of dependence on experimental trial and error in drug research and development. Sequoia China’s investment in Jingtai Technology It reflects our optimistic development prospects of artificial intelligence to drive the transformation of the pharmaceutical industry. The company has the advantage in technology, team and business model to become the leader in this field. It is expected that Sequoia China can help Jingtai Technology realize its value and grow into A successful and influential company."

Lin Yifan of Google Enterprise Investment Development said: "Jingtai Technology's artificial intelligence platform is a powerful drug development tool, and many important researchers have begun to apply. Their drug development technologies, such as ID4, can promote new drug development capabilities and Efficiency while reducing costs. We are honored to work with this powerful team and look forward to their future development."

“After obtaining Ten-A's investment in Tencent, Jingtai Technology has developed rapidly, and innovation in artificial intelligence drug research and development technology has been recognized by world-renowned pharmaceutical companies,” said Li Zhaohui, managing partner of Tencent Investment. "Tencent's additional investment in this round is that we are optimistic about the innovation and execution of the Jingtai Technology team, and we are confident in the future development of artificial intelligence-driven drug development."

SnSbCu Babbitt Wire

Babbitt wire is with tin as the base, the product is added with certain amount of antimony, copper

or other improved elements.

Sn Sb7Cu3 Babbit metal is suitable for metal spraying on the end face of metalized film capacitor. With strong adhesive force, good weldability and low loss angle, it is an ideal metal spraying material for laminated capacitor.

Other trade marks are suitable to use CMT, TIG and MIG technology to manufacture sliding bearing bush material layer. It is of high bonding strength with substrate, with material utilization rate of 70~80%. It has small amount of ingredient segregation without any loose or slag inclusion. The internal control standard of the alloy composition is prevailing over GB/T8740-2013. Babbi1 metal added with improved elements can substantially enhance the service life.

Snsbcu Babbitt Wire,Overlaying Materials,Thermal Spray Babbitt Wire,Babbitt Wire

Shaoxing Tianlong Tin Materials Co.,Ltd. , https://www.tianlongspray.com